Evgen Pharma PLC Grant of further European patent (8199M)

TIDMEVG

RNS Number : 8199M

Evgen Pharma PLC

02 May 2018

 
 For immediate release   2 May 2018 
 
 

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Grant of further European patent

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the grant of a key European patent ascribing intellectual property rights to the Company for a method of stabilising sulforaphane, the naturally occurring compound on which SFX-01, the Company's lead product, is based.

The grant of this core patent, which expires on 23 January 2028, marks another important step in expanding the Company's worldwide intellectual property estate surrounding sulforaphane and the Company's synthetic, stabilised version, SFX-01.

This patent represents the Company's second process patent grant in Europe and follows the announcement of a manufacturing and scale-up grant in October 2017. Composition-of-matter and manufacturing patents have already been granted in the USA. Patents are also granted, or in the process towards being granted, in other key commercial territories.

The European patent announced today, numbered EP2796140 and entitled Stablilized Sulforaphane, can be viewed at this link: https://register.epo.org/application?number=EP14166888&lng=en&tab=main.

Exclusive worldwide rights to the patent are held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs Inc., the US laboratory that invented SFX-01.

In line with Company policy, an update on less material patent developments, including grants related to the Company's sulforaphane analogues, will be included as part of the Company's full year results.

Steve Franklin, CEO of Evgen Pharma, said:

"We are delighted by the grant of this core patent in Europe, which further expands our intellectual property position and complements similar grants in the USA, Canada and Australia. This patent grant is timely from a commercial perspective as we are moving close to the announcement of our first Phase II clinical data from SFX-01, which we continue to expect in the first half of this year as part of our ongoing STEM trial in breast cancer."

Enquiries:

 
 Evgen Pharma plc                                        c/o [phone] 
  Dr Stephen Franklin, CEO                                              5000 
  Richard Moulson, CFO 
  www.evgen.com 
 
 Buchanan 
  Mark Court, Sophie Wills, Stephanie                        [phone] 
  Watson                                                                5000 
 
 Northland Capital Partners Limited 
  Matthew Johnson, Gerry Beaney, 
  Tom Price (Corporate Finance) 
  John Howes, Rob Rees (Corporate                            [phone] 
  Broking)                                                              6625 
 
 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUCUAUPRPGG

(END) Dow Jones Newswires

May 02, 2018 02:00 ET (06:00 GMT)